Cargando…

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

PURPOSE: The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance. The genes that associated with cisplatin resistance remain unclear. Herein, we aimed to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Zhen-duo, Hao, Lin, Han, Xiao-xiao, Wu, Zhuo-Xun, Pang, Kun, Dong, Yang, Qin, Jia-xin, Wang, Guang-yue, Zhang, Xuan-ming, Xia, Tian, Liang, Qing, Zhao, Yan, Li, Rui, Zhang, Shao-qi, Zhang, Jun-hao, Chen, Jian-gang, Wang, Gong-cheng, Chen, Zhe-Sheng, Han, Cong-hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819945/ https://www.ncbi.nlm.nih.gov/pubmed/35130920 http://dx.doi.org/10.1186/s12943-022-01517-9

Ejemplares similares

The nuclear matrix protein HNRNPU maintains 3D genome architecture globally in mouse hepatocytes
por: Fan, Hui, et al.
Publicado: (2018)

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
por: Wang, Yonggang, et al.
Publicado: (2018)

Germline pathogenic variants in HNRNPU are associated with alterations in blood methylome
por: Lee, Sunwoo, et al.
Publicado: (2023)

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
por: Shi, Zhen-Duo, et al.
Publicado: (2023)

Heterogeneous nuclear ribonucleoprotein U (HNRNPU) safeguards the developing mouse cortex
por: Sapir, Tamar, et al.
Publicado: (2022)

Long Noncoding RNA lncRHL Regulates Hepatic VLDL Secretion by Modulating hnRNPU/BMAL1/MTTP Axis
por: Shen, Xuan, et al.
Publicado: (2022)

ERH Interacts With EIF2α and Regulates the EIF2α/ATF4/CHOP Pathway in Bladder Cancer Cells
por: Pang, Kun, et al.
Publicado: (2022)

HNRNPU promotes the progression of triple-negative breast cancer via RNA transcription and alternative splicing mechanisms
por: Han, Bo-yue, et al.
Publicado: (2022)

Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression
por: Shi, Zhen-Duo, et al.
Publicado: (2023)

Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
por: Pang, Kun, et al.
Publicado: (2022)

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
por: Rajendran, Ganeshkumar, et al.
Publicado: (2021)

hnRNPU in Sertoli cells cooperates with WT1 and is essential for testicular development by modulating transcriptional factors Sox8/9
por: Wen, Yujiao, et al.
Publicado: (2021)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Expanding the phenotype of HNRNPU ‐related neurodevelopmental disorder with emphasis on seizure phenotype and review of literature
por: Taylor, James, et al.
Publicado: (2022)

The RNA-binding protein hnRNPU regulates the sorting of microRNA-30c-5p into large extracellular vesicles
por: Zietzer, Andreas, et al.
Publicado: (2020)

Role of NRP1 in Bladder Cancer Pathogenesis and Progression
por: Dong, Yang, et al.
Publicado: (2021)

Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2017)

Analysis of the nucleocytoplasmic shuttling RNA-binding protein HNRNPU using optimized HITS-CLIP method
por: Yugami, Masato, et al.
Publicado: (2020)

Evidence of shared transcriptomic dysregulation of HNRNPU-related disorder between human organoids and embryonic mice
por: Ressler, Andrew K., et al.
Publicado: (2022)

Neurodevelopmental deficits and cell-type-specific transcriptomic perturbations in a mouse model of HNRNPU haploinsufficiency
por: Dugger, Sarah A., et al.
Publicado: (2023)

A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer
por: Dong, Yang, et al.
Publicado: (2021)

Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1
por: Yang, Fan, et al.
Publicado: (2023)

Solasonine Induces Apoptosis and Inhibits Proliferation of Bladder Cancer Cells by Suppressing NRP1 Expression
por: Dong, Yang, et al.
Publicado: (2022)

circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression
por: Li, Hongjun, et al.
Publicado: (2023)

Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release
por: Li, Xun, et al.
Publicado: (2013)

CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response
por: Wavelet-Vermuse, Cindy, et al.
Publicado: (2022)

RETRACTED ARTICLE: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
por: Song, Huajie, et al.
Publicado: (2020)

Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression
por: Song, Huajie, et al.
Publicado: (2023)

CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming
por: Li, Mengxuan, et al.
Publicado: (2022)

Integrated single‐cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial–fibroblast interactions in recurrent bladder cancer
por: Shi, Zhen‐Duo, et al.
Publicado: (2023)

piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination
por: Zhang, Wentao, et al.
Publicado: (2023)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

Novel potential urinary biomarkers for effective diagnosis and prognostic evaluation of high-grade bladder cancer
por: Zhang, Zhi-Guo, et al.
Publicado: (2023)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells
por: Hao, Lin, et al.
Publicado: (2017)

OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells
por: Wang, Dailian, et al.
Publicado: (2018)

Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR‐1270 inhibition
por: Yuan, Wenbo, et al.
Publicado: (2019)

Knockdown of P3H4 inhibits proliferation and invasion of bladder cancer
por: Hao, Lin, et al.
Publicado: (2020)

Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT
por: Zhou, Hong-Hao, et al.
Publicado: (2016)

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
por: Chen, Jinbo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vmfobgbdkf08ejtd0j00hnuqei